Drug Profile


Alternative Names: AG 014699; AG-14699; CO-338; PF-01367338; PF-1367338; Rubraca; Rucaparib camsylate

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cancer Research UK
  • Developer Cancer Research UK; Clovis Oncology; Roche; UNICANCER
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Indoles; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Phase III Fallopian tube cancer; Peritoneal cancer; Prostate cancer
  • Phase II Breast cancer; Pancreatic cancer
  • Phase I Gynaecological cancer; Solid tumours
  • Suspended Malignant melanoma

Most Recent Events

  • 31 Jul 2017 Bristol-Myers Squibb and Clovis Oncology enter into clinical trial collaboration agreement to develop rucaparib in combination with nivolumab for Ovarian, Fallopian tube, Peritoneal, Breast and Prostate cancers in USA, Europe and additional countries
  • 31 Jul 2017 Clovis Oncology announces intention to submit MAA to the EMA for Ovarian cancer (Second-line therapy or greater, Maintenance therapy) in early 2018
  • 31 Jul 2017 Clovis Oncology announces intention to submit sNDA to the US FDA for Ovarian cancer (Second-line therapy or greater, Maintenance therapy) by October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top